Broken String Biosciences, headquartered at the Wellcome Genome Campus in Cambridge, UK, is dedicated to advancing genome editing technologies. The company's focus lies in expediting the characterisation of innovative genome editing techniques, which holds the key to the next generation of cell and gene therapies.

With a commitment to enhancing safety, efficiency, and affordability of cell and gene therapies, Broken String Biosciences has developed the INDUCE-seq™ DNA break mapping technology. This data-driven platform provides intricate insights into the precise interactions between genome editors and the human genome, playing a pivotal role in the development of efficient genome editing systems. Moreover, it opens up numerous new therapeutic targets within the genome, driving progress in therapeutic development.